Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 18/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650295 | 0.78 | F2RL3 (0.44) | F2RL3TP53EGFR | |
| SCHEMBL452295 | 0.77 | F2RL3 (0.46) | F2RL3TP53 | |
| SCHEMBL624035 | 0.68 | SMN1; SMN2 (0.40) | TP53 | |
| SCHEMBL19434320 | 0.67 | TP53 (0.51) | F2RL3TP53 | |
| SCHEMBL3476148 | 0.66 | F2RL3 (0.65) | F2RL3TP53 | |
| SCHEMBL627767 | 0.66 | L3MBTL1 (0.44) | — | |
| SCHEMBL19306633 | 0.64 | TP53 (0.55) | F2RL3TP53EGFR | |
| SCHEMBL453907 | 0.62 | — | — | |
| SCHEMBL19434394 | 0.62 | F2RL3 (0.43) | F2RL3TP53 | |
| SCHEMBL452502 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| US-9808466-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 2017-11-07 | — | — | US | disclosed |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2016-10-13 | — | — | US | disclosed |
| US-9284334-B2 | Macrocyclic compounds as protein kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2016-03-15 | — | — | US | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| EP-2710018-A2 | NEW COMPOUNDS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012156756-A2 | NEW COMPOUNDS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-11-22 | — | — | WO | disclosed |
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-19 | — | — | US | disclosed |
| WO-2011121317-A9 | IMIDAZOTHIADIAZOLES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012020217-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |
| EP-2414369-A1 | IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-08 | — | — | EP | disclosed |
| WO-2011121317-A1 | IMIDAZO [2,1-B] [1,3,4] THIADIAZOLES AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010112874-A1 | IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | PIK3CA, PI4KA, PIK3CD | F2RL3 2944/4885TP53 344/4885EGFR 464/4885 |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | F2RL3 2592/4885TP53 4590/4885EGFR 4687/4885 |
| US-20160296528-A1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIM1, PIM3, PIM2 | F2RL3 3219/4885TP53 430/4885EGFR 248/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | F2RL3 1899/4885TP53 133/4885EGFR 1320/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | F2RL3 2592/4885TP53 4590/4885EGFR 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.